TABLE 3.
Summary results on the characteristics of patients with ICIs-P.
| Characteristic | All cases (N = 61) |
|---|---|
| Age, years | |
| Median (range) | 58 (23–82) |
| Gender | N (%) |
| Male/Female, N (%) | 37(60.7)/24(39.3) |
| Tumor type | N (%) |
| Melanoma | 18 (29.5) |
| NSCLC | 16 (26.2) |
| RCC | 6 (9.8) |
| UC | 2 (3.3) |
| metrocarcinoma | 2 (3.3) |
| Other Tumor | 17 (27.9) |
| Agent(ICIs) | N (%) |
| Pembrolizumab | 23 (37.7) |
| Nivolumab | 17 (27.9) |
| Toripalimab | 3 (4.9) |
| Atezolizumab | 2 (3.3) |
| Nivolumab + Ipilimumab | 7 (11.5) |
| Ipilimumab + Pembrolizumab | 4 (6.5) |
| Pembrolizumab + bevacizumab | 1 (1.6) |
| Other ICIs (Frequency only 1 time) | 4 (6.5) |
| ICIs type | N (%) |
| Anti-PD-1/L1 | 48 (78.7) |
| Anti-CTLA-4 | 1 (1.6) |
| Combination | 12 (19.7) |
| The median time of onset, day (min-max) [IQR] | 108 (1–1,020) [52–278] |
| Symptoms | N (%)# |
| Typical symptoms of pancreatitis | 46 (78.0) |
| Asymptomatic | 9 (15.2) |
| Nonspecific symptoms | 4 (6.8) |
| Elevation of serum amylase or lipase | N (%) |
| Yes/No | 55(90.2)/6(9.8) |
| Imaging findings of pancreatitis | N (%)# |
| Yes/No | 53(91.4)/5(8.6) |
| Grading of pancreatitis | N (%) |
| G3-G4 | 39 (64.0) |
| G2 | 15 (24.5) |
| G1 | 7 (11.5) |
| Other immune-related adverse events | N (%)* |
| Colitis | 8 (12.3) |
| Hepatobiliary injury | 12 (18.5) |
| Dysthyroidism (hyper/hypo) | 5 (7.6) |
| Gastritis | 2 (3.1) |
| Hyperlipemia | 3 (4.6) |
| Other irAEs | 6 (9.2) |
| None | 29 (44.6) |
| Treatment of pancreatitis | N (%) |
| Intravenous fluids | 6 (9.8) |
| Steroids/Steroids and other treatments | |
| For pancreatitis only | 27 (44.3) |
| For other reasons also | 18 (29.5) |
| Discontinuation of ICIs therapy only | 2 (3.3) |
| Other | 8 (13.1) |
| Management of ICIs | N (%)# |
| Permanently discontinued | 30 (58.8) |
| Temporarily discontinued, then restarted | 7 (13.7) |
| Continued | 3 (5.9) |
| Treatment already completed at the onset | 11 (21.6) |
| Outcome | N (%) |
| Improvement | 51 (83.6) |
| Death | 5 (8.2) |
| Recurrence | 5 (8.2) |
Abbreviations: #Some articles are not available; *Some cases had multiple adverse reactions; ICIs-P, Immune checkpoint inhibitors-induced pancreatitis; N,number; NSCLC, non-small cell lung carcinoma; RCC, renal cell carcinoma; UC, urothelial carcinoma; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; CTLA-4, cytotoxic T lymphocyte antigen 4; IQR, interquartile range.